Literature DB >> 9446016

[Docetaxel (taxotere) for therapy of breast carcinoma. Highest effectiveness with moderate side effects].

G von Minckwitz1, S D Costa.   

Abstract

CLINICAL
RESULTS: Docetaxel is a taxan which has proven high efficacy in the treatment of breast cancer. The results are consistent throughout all phases of clinical evaluation. High response rates have been observed especially for women after failure of anthracyclins or with liver metastases. Response rates are superior to doxorubicin, while the extent of the side effects is comparable.
CONCLUSION: Due to the different toxicity profile a combination of docetaxel and anthracyclins is feasible and has already been demonstrated in early clinical trials. The role of the combinatory treatments in first line or adjuvant setting is currently under investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9446016     DOI: 10.1007/bf03041969

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  8 in total

1.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

Authors:  I Ringel; S B Horwitz
Journal:  J Natl Cancer Inst       Date:  1991-02-20       Impact factor: 13.506

2.  High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

Authors:  J B Vermorken; W W ten Bokkel Huinink; I A Mandjes; T J Postma; M T Huizing; J J Heimans; J H Beijnen; F Bierhorst; B Winograd; H M Pinedo
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

3.  Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

Authors:  S Jones; E Winer; C Vogel; L Laufman; L Hutchins; M O'Rourke; B Lembersky; D Budman; J Bigley; J Hohneker
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

4.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

Authors:  L Gianni; E Munzone; G Capri; F Fulfaro; E Tarenzi; F Villani; C Spreafico; A Laffranchi; A Caraceni; C Martini
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

5.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Authors:  A D Seidman; A Tiersten; C Hudis; M Gollub; S Barrett; T J Yao; J Lepore; T Gilewski; V Currie; J Crown
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

6.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.

Authors:  J M Extra; F Rousseau; R Bruno; M Clavel; N Le Bail; M Marty
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

Review 7.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

Review 8.  Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

Authors:  A T van Oosterom; D Schrijvers; D ] Schriivers D [corrected to Schrijvers
Journal:  Anticancer Drugs       Date:  1995-06       Impact factor: 2.248

  8 in total
  1 in total

1.  Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.

Authors:  Xinrong Guo; Sibylle Loibl; Michael Untch; Volker Möbus; Kathrin Schwedler; Peter A Fasching; Jana Barinoff; Frank Holms; Christoph Thomssen; Dirk M Zahm; Rolf Kreienberg; Maik Hauschild; Holger Eidtmann; Sascha Tauchert; Keyur Mehta; Gunter von Minckwitz
Journal:  Breast Care (Basel)       Date:  2011-08-19       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.